We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Compounded outcomes associated with comorbid Alzheimer's disease & cerebrovascular disease
News

Compounded outcomes associated with comorbid Alzheimer's disease & cerebrovascular disease

Compounded outcomes associated with comorbid Alzheimer's disease & cerebrovascular disease
News

Compounded outcomes associated with comorbid Alzheimer's disease & cerebrovascular disease

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Compounded outcomes associated with comorbid Alzheimer's disease & cerebrovascular disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Two studies by researchers at the Sanders-Brown Center on Aging find similar results with different mouse models

Researchers from the Sanders-Brown Center on Aging at the University of Kentucky have been able to confirm anecdotal information on patients with both Alzheimer's disease (AD) and cerebrovascular disease (CVD) using mouse models in two different studies.


The findings of these two studies, which were recently published in Acta Neuropathologica and Alzheimer's Research & Therapy, have potentially significant implications for patients with both disorders.


Both papers studied CVD in Alzheimer's disease mouse models using different lifestyle factors.


Paul Murphy, Ph.D, and his group studied the combined effects of type 2 diabetes, Alzheimer's disease, and cerebrovascular disease in a novel mouse genetic model.


Donna Wilcock, Ph.D, and her group used a different mouse model to study the effects of Alzheimer's disease and hyperhomocysteinemia on cognition. An elevated level of homocysteine is associated with a number of disease states, including CVD.


According to Wilcock, both papers came to similar conclusions.


"We found that, while the primary Alzheimer's pathologies were unchanged, the learning and memory outcomes were significantly worse. In other words, in our mouse models, the cognitive effects of Alzheimer's disease combined with cerebrovascular disease were compounded both in terms of severity and the speed of decline," Wilcock says.


Murphy emphasizes the significance of the findings, particularly since approximately 40% of Alzheimer's patients also have cerebrovascular disease.


"We are really excited about these results," Murphy said. "Until now, we have had almost no way to study how Alzheimer's and cerebrovascular disease interact. These new mouse models give us a way to test ideas about the disease, and ultimately develop ways to treat it."


Note: Material may have been edited for length and content. For further information, please contact the cited source.

University of Kentucky   press release


Publication

Tiffany L Sudduth, Erica M Weekman, Holly M Brothers, Kaitlyn Braun, Donna M Wilcock. ß-amyloid deposition is shifted to the vasculature and memory impairment is exacerbated when hyperhomocysteinemia is induced in APP/PS1 transgenic mice.   Alzheimer's Research & Therapy, Published June 9 2014. doi: 10.1186/alzrt262


Advertisement